Molecular-Genetic Mechanisms Associated With Chemotherapy-Induced Nerve Damage
Stopped early
Conditions studied: Peripheral Neuropathic Pain, Neurotoxicity, Cancer
In brief
Background: \- Docetaxel, the most commonly used drug for the treatment of invasive breast cancer, has been shown to prolong the lives of women with breast cancer and prevent the cancer from spreading or returning. However, docetaxel is known to cause nerve damage, including numbness, tingling, and pain, in 50 to 90 percent of breast cancer patients. This nerve damage is called peripheral neuropathy, and can be so severe that treatment with docetaxel may need to be stopped. Researchers are interested in studying docetaxel-related nerve damage to determine whether certain genetic factors may predispose women to developing this condition, and to more closely investigate the specific effects of docetaxel on the nervous system Objectives: \- To examine nerve damage in women with breast cancer who are being treated with docetaxel. Eligibility: \- Women at least 18 years of age who have been diagnosed with invasive breast cancer and are scheduled to have docetaxel treatment. Design: * Participants will be screened with a full medical history and physical examination, as well as blood and urine tests and imaging studies. * This study requires seven visits, one before the start of chemotherapy and six after the scheduled treatment visits. Study procedures at each visit will take 30 to 45 minutes and will be done in parallel with scheduled chemotherapy visits. * At the first visit, participants will provide blood samples; complete questionnaires to rate and describe any existing pain, numbness, or tingling in hands and feet before the start of chemotherapy; have nerve conduction tests; and have a skin biopsy. * At each visit following docetaxel treatment, participants will complete questionnaires to rate and describe any pain, numbness, or tingling during the course of chemotherapy. Participants will provide blood samples at every visit and have nerve conduction tests during the second, fourth, and sixth visits. Participants will also have a second skin biopsy, either from a site that appears to be experiencing nerve damage or (for those who are not developing nerve damage symptoms) from a site near the first biopsy location.
Key facts
- Study ID
- NCT01293851
- Run by
- National Institute of Nursing Research (NINR)
- People needed
- 3
- Starts
- 2010-12-22
- Expected to finish
- 2012-11-13
- Last updated by the study team
- 2019-12-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Patients with any one of the following will be excluded:
- Unable to provide their own informed consent
- Have had prior radiotherapy
- Pre-existing documented neuropathy or risk factors for neuropathy that may confound the analysis of factors associated with CIPN such as:
- Diabetes mellitus
- Uremia
- Vitamin B12 deficiency
- Peripheral vascular disease
- Documented Thyroid dysfunction with on-going treatment. The patients who have thyroid dysfunction may also manifest the peripheral neuropathic symptoms such as numbness and tingling on their feet and hands. The medications used to treat hypothyroidism may confound the study data assessment.
- Previous history of alcoholism (beriberi) or drug abuse
- Rheumatoid arthritis
- Lupus
- Amyloidosis
- Sarcoidosis
- Other drug-induced neuropathy that may confound the analysis associated with CIPN such as:
- Thalidomide
- Isoniazid
- Trichloroethylene
- Hydralazine
- Disulfiram
- Nitrofurantoin
Where it is running
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.